|
Patent landscape, scope, and claims: |
United States Patent 8,309,060: Abuse-Proofed Thermoformed Dosage Forms With High-MW Polymer and Optional Aversion Package
US Drug Patent 8,309,060 claims an abuse-resistant dosage form built around thermoforming, a specific high molecular weight polymer class, and a minimum mechanical breaking strength, with optional wax and an optional “aversion package” intended to deter non-oral abuse routes. The claim set also covers tablet and multiparticulate embodiments, controlled release configurations, a melt/granulation production approach, and therapeutic use for pain and other conditions.
What is the core claimed invention?
Structural requirements in independent claim 1
Claim 1 defines an “abuse-proofed, thermoformed dosage form” with the following required elements:
-
Dosage form type
- “thermoformed dosage form”
-
Drug payload
- “one or more active ingredients with abuse potential (A)”
- (A) is optionally combined with “physiologically acceptable auxiliary substances (B)”
-
Polymer carrier/abuse-resistant matrix
- includes at least one synthetic or natural polymer (C)
- polymer (C) has a molecular weight of at least 0.5 million “according to rheological measurements”
- polymer (C) is optional to the degree that it is required by claim 1; the claim language makes it mandatory
-
Optional wax
- includes optionally at least one wax (D)
-
Mechanical abuse resistance
- dosage form exhibits breaking strength of at least 500 N
Claim 1 in compact logic
- Abuse-proofed + thermoformed
- Includes A (+ optional B)
- Must include polymer C, MW ≥ 0.5 million (rheology)
- Wax D optional
- Breaking strength ≥ 500 N
How do dependent claims narrow the scope?
Dosage form format
The patent narrows into concrete physical formats:
- Claim 2: tablet
- Claim 3: multiparticulate form
Polymer species limitation
- Claim 4: polymer (C) is selected from:
- polyethylene oxide, polymethylene oxide, polypropylene oxide
- polyethylene, polypropylene
- polyvinyl chloride, polycarbonate, polystyrene
- polyacrylate
- copolymers and mixtures
Polymer MW window
- Claim 5: molecular weight is 1–15 million
Wax identity and softening point
- Claim 6: wax (D) has:
- Claim 7: wax is carnauba wax or beeswax
Active ingredient class scope
- Claim 8: A is selected from:
- opiates, opioids, tranquillisers, stimulants, barbiturates, further narcotics
- Claims 31 and 34 provide specific opioids:
- oxymorphone, oxycodone, tapentadol and salts
“Aversion package” components (claims 9–21)
Claim 9 adds a broad optional package of components a–f:
a. Irritant for nasal passages and/or pharynx
b. Viscosity-increasing agent that forms a gel with extract obtained from dosage form (with minimal aqueous liquid), with gel optionally visually distinguishable
c. Antagonist for abuse-potential actives
d. Emetic
e. Dye as aversive agent
f. Bitter substance
Key dependent claim narrowing within the aversion package:
-
Claim 10: irritant causes burning, itching, urge to sneeze, increased secretions, or a combination
-
Claim 11: irritant is based on constituents of a “hot substance drug”
-
Claim 12: hot substance drug examples include garlic, asarum, calamus, capsicum (including cayenne), turmeric (multiple species), galangal, nutmeg, pepper, mustard seeds, zedoary, ginger
-
Claim 13–14: constituent chemical families and named constituents, including:
- o-methoxy(methyl)phenol compounds, acid amide compounds, mustard oils, sulfides
- myristicin, elemicin, isoeugenol, β-asarone, safrole, gingerols, xanthorrhizol, capsaicinoids, piperine, glucosinolates and derivatives
-
Claim 15: viscosity-increasing agents enumerated, including:
- microcrystalline cellulose + 11 wt% CMC-Na (Avicel® RC 591)
- CMC-Na grades (Blanose®, CMC-Na C300P®, Frimulsion BLC-5®, Tylose C300 P®)
- Carbopol® 980/981 (polyacrylic acid)
- locust bean flour, citrus pectin, waxy maize starch (C*Gel)
- sodium alginate, guar flour, iota carrageen, karaya gum, gellan gum
- galactomannan, tara bean flour, propylene glycol alginate
- sodium hyaluronate, pectin varieties
- tragacanth, tara gum, welan gum, xanthan gum
-
Claim 16: opioid antagonists include naloxone, naltrexone, nalmefene, nalid, nalmexone, nalorphine, naluphine and physiologically acceptable compounds
-
Claim 17: includes “neuroleptic stimulant antagonist”
-
Claim 18: emetic based on ipecac constituents and/or apomorphine
-
Claim 19: physiologically acceptable dye
-
Claim 20: bitter substances including aromatic oils, fruit aroma substances, denatonium benzoate
-
Claim 21: spatial separation architecture:
- A is spatially separated from antagonist (c) and/or emetic (d) and/or bitter (f)
- A may be in subunit X, while components c/d/f are in subunit Y
- intended effect: when administered correctly, c/d/f from Y do not exert their effect in the body or upon taking
Controlled release coverage
- Claim 22: at least one active ingredient is controlled release
- Claim 23: each abuse-potential active (A) is present in controlled release matrix
- Claim 24: polymer (C) and/or wax (D) serve as controlled release matrix material
Process claims and production mechanics
- Claim 25: mixing A, B, C and optional D; plus optional a–f; optionally after granulation; press-forming; with heat exposure before, simultaneous, or subsequent
- Claim 26: granulation performed via a melt process
- Claim 27: dosage form obtainable by claim 25 process
Method of treatment
- Claim 28: administering dosage form of claim 1 for therapeutic condition
- Claim 29: therapeutic condition is pain
What is the effective claim boundary in practice?
Minimum enforceable “hard points”
If a competitor wants freedom-to-operate (FTO) design-around, they must avoid at least one mandatory element of claim 1:
- thermoformed dosage form
- polymer C with:
- MW ≥ 0.5 million (rheological measurement standard)
- breaking strength ≥ 500 N
- includes abuse-potential active ingredient(s)
Everything else (auxiliaries B, wax D, aversion package a–f, controlled release features) is optional via dependent claims or claim 9’s structure. That creates a broad baseline with selective enhancements.
Quantitative narrowing layers
The patent also adds numeric/identity constraints through dependent claims that can still matter in infringement analysis when those dependent claims are asserted alongside independent claim 1:
- polymer MW 1–15 million (claim 5)
- wax softening point ≥ 60°C (claim 6)
- wax specifically carnauba/beeswax (claim 7)
- opioid exemplars oxymorphone/oxycodone/tapentadol (claims 31, 34)
- polymer content ≥ 30 wt% (claim 33, and claim 34 ties to the opioid set + MW range)
How broad are the ingredient and additive lists?
Active ingredient set breadth
- Broad “abuse potential” category in claim 8 includes multiple drug classes.
- Narrower opioid examples in claims 31 and 34 anchor to mainstream opioid targets used in abuse-resistant formulation.
Aversion package breadth
The aversion package in claim 9 is wide in category coverage and also wide in constituent examples:
- irritants can be derived from a defined “hot substance drug” menu and from specified chemical families
- viscosity agents are extensively enumerated including cellulose derivatives, gums, pectins, alginates, carrageenans, gellan, hyaluronate, and xanthan class
- antagonists include several named opioid antagonists
- emetics and bitter/dye options are defined by category and example list
Polymer set breadth
Claim 4 lists a wide polymer universe spanning:
- high-MW polyethylene oxide / polyethylene derivatives
- polyolefins (polyethylene/propylene)
- vinyl chloride, polycarbonate, polystyrene
- polyacrylate, plus copolymers and mixtures
The commonality is not polymer chemistry but the rheology-based molecular weight threshold and the mechanical breaking strength outcome.
Claim architecture relevant to litigation and prosecution
Two tiers: base abuse-resistant matrix vs. modular deterrents
- Tier 1 (mandatory): thermoformed dosage form + high-MW polymer + breaking strength
- Tier 2 (optional enhancements):
- wax-limited embodiments (softening point threshold)
- aversion system (irritant/gel/antagonist/emetic/dye/bitter)
- controlled release and matrix function (polymer and wax as matrix)
- spatial separation via subunits X and Y
The spatial separation claim (21) is notable because it creates a formulation architecture that reduces unintended effects during correct use. It is an “abuse prevention without physiological penalty” design pathway that could be used as an alternative design-around target by competitors.
Patent landscape: what claim themes imply for competitors
This patent is a formulation-and-process patent with mechanical performance and material characterization thresholds. The landscape impact comes from how the claim themes align with common abuse-resistant strategy components.
Landscape themes likely to cluster around this patent
-
Mechanical robustness thresholds
- breaking strength ≥ 500 N is a direct, testable parameter that can anchor future infringement disputes around testing protocol and thermoforming conditions.
-
High-MW polymer rheology
- MW is defined “according to rheological measurements,” not solely via nominal characterization. That can expand evidentiary battles and supports continued patenting around polymer selection and measurement method.
-
Controlled release matrix integration
- claims 22–24 create overlap with controlled release abuse-deterrence systems using polymer or wax as the release matrix.
-
Aversion add-ons
- claim 9 and its dependent embodiments capture an “aversion package” approach that often recurs in multiple abuse-deterrent patent families, including irritants, antagonists, emetics, dyes, and bitter compounds.
-
Heat/granulation press-forming processes
- claim 25 and 26 tie to production: mixing + optional granulation + press-forming with heat exposure; with melt-process granulation.
What these themes mean for freedom-to-operate
Potential risk zones are companies:
- using thermoforming and press-forming with high-MW polymers in abuse-resistant opioid tablets/multiparticulates,
- using specific waxes meeting softening point threshold,
- using spatially separated antagonist/emetic/bitter subunits,
- and/or using controlled release matrices where polymer/wax serve as the matrix material.
Detailed claim-by-claim scope map (what is covered)
| Claim |
Coverage type |
Key limitations |
| 1 |
Independent |
thermoformed abuse-proofed dosage form; A (+ optional B); polymer C MW ≥ 0.5M (rheology); optional wax D; breaking strength ≥ 500 N |
| 2 |
Dependent |
tablet |
| 3 |
Dependent |
multiparticulate |
| 4 |
Dependent |
polymer C from specific polymer families/mixtures |
| 5 |
Dependent |
MW 1–15 million |
| 6 |
Dependent |
wax softening point ≥ 60°C |
| 7 |
Dependent |
wax = carnauba wax or beeswax |
| 8 |
Dependent |
A = opiates/opioids/tranquillisers/stimulants/barbiturates/narcotics |
| 9 |
Dependent |
adds components a–f (irritant, viscosity gel former, antagonist, emetic, dye, bitter) |
| 10–14 |
Dependent |
irritant type and “hot substance drug” constituent lists |
| 15 |
Dependent |
specific viscosity-increasing agents list |
| 16–20 |
Dependent |
specific antagonists/emetic/dye/bitter options |
| 21 |
Dependent |
spatial separation via subunits X (A) and Y (c/d/f), intended non-effect during correct administration |
| 22–24 |
Dependent |
controlled release; controlled release matrix uses polymer and/or wax |
| 25–27 |
Process |
mixing + optional granulation + press-forming + heat exposure; melt granulation option; dosage form obtainable by process |
| 28–29 |
Use |
method to treat condition; includes pain |
| 30 |
Dependent |
polymer C = polyethylene oxide; MW 1–15 million g/mol |
| 31–34 |
Dependent |
opioid exemplars (oxymorphone/oxycodone/tapentadol); tablet; ties with polyethylene oxide MW and polymer ≥ 30 wt% |
Key Takeaways
- US 8,309,060 claims an abuse-proofed, thermoformed dosage form anchored on a high-MW polymer (C) and a minimum breaking strength of 500 N; wax and an aversion package are optional add-ons via dependent claims.
- The patent’s enforceable “spine” is claim 1: thermoforming + rheology-defined high molecular weight polymer + mechanical breaking strength applied to abuse-potential actives.
- Dependent claims materially expand coverage into tablet and multiparticulate forms, specific polymer species and MW bands, specific wax types and softening points, opioid-specific embodiments, controlled release matrix configurations, and spatially separated aversion components.
- Process claims (mixing + optional granulation + press-forming with heat; melt granulation) provide an additional infringement pathway beyond product configuration.
FAQs
-
Does the patent require controlled release?
No. Controlled release appears in dependent claims (22–24). Claim 1 does not require controlled release.
-
Is the wax mandatory?
No. Wax (D) is optional in claim 1, then made constrained in dependent claims (6–7).
-
What polymers qualify?
Claim 4 lists many candidate polymer types, while claim 5 narrows the molecular weight to 1–15 million; claim 30 further specifies polyethylene oxide as a specific embodiment.
-
What is the central abuse-resistance metric?
Claim 1 uses a mechanical threshold: breaking strength of at least 500 N.
-
Can aversion actives affect the user during correct administration?
Claim 21 targets this by requiring spatial separation so that antagonist/emetic/bitter components in subunit Y do not exert their effect when administered correctly.
References
[1] United States Patent 8,309,060.
More… ↓
⤷ Start Trial
|
